Erratum: Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial (The Lancet (2017) 390(10090) (135–144), (S0140673617309303) (10.1016/S0140-6736(17)30930-3));Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

The Lancet

Volumn 390, Issue 10090, 2017, Pages 135-144

  Vermeire, Séverine ^a   Sandborn, William J ^b   Danese, Silvio ^c   Hébuterne, Xavier ^d   Salzberg, Bruce A ^e   Klopocka, Maria ^f   Tarabar, Dino ^g   Vanasek, Tomas ^h   Greguš, Miloš ⁱ   Hellstern, Paul A ^j   Kim, Joo Sung ^k   Sparrow, Miles P ^l   Gorelick, Kenneth J ^m   Hinz, Michelle ^m   Ahmad, Alaa ^m   Pradhan, Vivek ^m   Hassan Zahraee, Mina ^m   Clare, Robert ^m   Cataldi, Fabio ^m   Reinisch, Walter ^n,o  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HUMANITAS UNIVERSITY   (Italy)

^d UNIVERSITY HOSPITAL OF NICE   (France)

^e Atlanta Gastroenterology Specialists PC   (United States)

^f NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^g UNIVERSITY OF DEFENCE   (Serbia)

^h CHARLES UNIVERSITY   (Czech Republic)

ⁱ Gastroenterology Center   (Slovakia)

^j Nature Coast Clinical Research   (United States)

^k Seoul National University College of Medicine   (South Korea)

^l ALFRED HOSPITAL   (Australia)

^m PFIZER INC   (United States)

ⁿ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^o MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; PF 00547659; PLACEBO; UNCLASSIFIED DRUG; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY; PF-00547659; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; ATTRIBUTABLE RISK; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; INFECTION; INFESTATION; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; REMISSION; TREATMENT DURATION; ULCERATIVE COLITIS; VOMITING; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 85019363567     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)33014-9     Document Type: Erratum

References (23)

1. Ungaro, R, Mehandru, S, Allen, PB, Peyrin-Biroulet, L, Colombel, J-F, Ulcerative colitis. Lancet 389 (2017), 1756–1770.
2. Ford, AC, Moayyedi, P, Hanauer, SB, Ulcerative colitis. BMJ, 346, 2013, f432.
3. Molodecky, NA, Soon, IS, Rabi, DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142 (2012), 46–54 e42.
4. Allocca, M, Fiorino, G, Vermeire, S, Reinisch, W, Cataldi, F, Danese, S, Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target. Expert Rev Clin Immunol 10 (2014), 885–895.
5. Ghosh, S, Panaccione, R, Anti-adhesion molecule therapy for inflammatory bowel disease. Therap Adv Gastroenterol 3 (2010), 239–258.
6. Briskin, M, Winsor-Hines, D, Shyjan, A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 151 (1997), 97–110.
7. Parikh, A, Leach, T, Wyant, T, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 18 (2012), 1470–1479.
8. Pullen, N, Molloy, E, Carter, D, et al. Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody. Br J Pharmacol 157 (2009), 281–293.
9. Schroeder, KW, Tremaine, WJ, Ilstrup, DM, Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317 (1987), 1625–1629.
10. Gottlieb, K, Travis, S, Feagan, B, Hussain, F, Sandborn, WJ, Rutgeerts, P, Central reading of endoscopy endpoints in inflammatory bowel disease trials. Inflamm Bowel Dis 21 (2015), 2475–2482.
11. Mehrotra, DV, Railkar, R, Minimum risk weights for comparing treatments in stratified binomial trials. Stat Med 19 (2001), 811–825.
12. Walmsley, RS, Ayres, RC, Pounder, RE, Allan, RN, A simple clinical colitis activity index. Gut 43 (1998), 29–32.
13. Calabrese, EJ, Blain, RB, The hormesis database: the occurrence of hormetic dose responses in the toxicological literature. Regul Toxicol Pharmacol 61 (2011), 73–81.
14. Feagan, BG, Rutgeerts, P, Sands, BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369 (2013), 699–710.
15. Vermeire, S, O'Byrne, S, Keir, M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 384 (2014), 309–318.
16. Feagan, BG, Sandborn, WJ, D'Haens, G, et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 145 (2013), 149–157 e2.
17. Sheridan, BS, Lefrancois, L, Intraepithelial lymphocytes: to serve and protect. Curr Gastroenterol Rep 12 (2010), 513–521.
18. Serriari, NE, Eoche, M, Lamotte, L, et al. Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases. Clin Exp Immunol 176 (2014), 266–274.
19. Jung, Y, Rothenberg, ME, Roles and regulation of gastrointestinal eosinophils in immunity and disease. J Immunol 193 (2014), 999–1005.
20. D'Haens, G, Ferrante, M, Vermeire, S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 18 (2012), 2218–2224.
21. De Vos, M, Dewit, O, D'Haens, G, et al. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNFα naïve patients with ulcerative colitis. J Crohns Colitis 6 (2012), 557–562.
22. Sipponen, T, Björkesten, CG, Färkkilä, M, Nuutinen, H, Savilahti, E, Kolho, KL, Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol 45 (2010), 325–331.
23. Henriksen, M, Jahnsen, J, Lygren, I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 57 (2008), 1518–1523.